Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

Leukemia, Myeloid, Acute 28Myelodysplastic Syndromes 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Leukemia, Lymphocytic, Chronic, B-Cell 13Lymphoma, Non-Hodgkin 12Lymphoma 12Recurrence 11Multiple Myeloma 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11Leukemia 9Leukemia, Biphenotypic, Acute 8Ovarian Neoplasms 7Neoplasms 7Lymphoma, Mantle-Cell 7Myeloproliferative Disorders 6Melanoma 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell 6Hodgkin Disease 6Hematologic Neoplasms 6Lymphoma, Follicular 5Immunoproliferative Disorders 5Immune System Diseases 5Lymphoproliferative Disorders 4Lymphoma, B-Cell, Marginal Zone 4Lymphatic Diseases 4Carcinoma, Non-Small-Cell Lung 4Sarcoma 3Mesothelioma 3Lung Neoplasms 3

Interventions

Radiotherapy 4Radiation 4Nivolumab 4Ipilimumab 3CTLA-4 Antigen 3Specimen Handling 2Magnetic Resonance Spectroscopy 2Biopsy 2talimogene laherparepvec 1pazopanib 1futibatinib 1fludarabine 1cabozantinib 1aldesleukin 1Ifosfamide 1Erlotinib Hydrochloride 1Doxorubicin 1Cyclophosphamide 1BO-112 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Histiocytoma, Malignant Fibrous × fludarabine × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡